Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Visual hallucinations

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Visual hallucinations. Displaying page 1 of 1.
    EudraCT Number: 2008-006278-13 Sponsor Protocol Number: NL24092.042.08 Start Date*: 2009-02-04
    Sponsor Name:UMCG
    Full Title: Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations.
    Medical condition: patients with advanced (>5 years) Parkinson's disease and visual hallucinations.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047570 Visual hallucinations LLT
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000102-11 Sponsor Protocol Number: NL55949 Start Date*: 2016-11-23
    Sponsor Name:University Medical Center Groningen
    Full Title: Randomized, double-blind, placebo-controlled trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with refractory visual hallucinations.
    Medical condition: Parkinson's disease patients with refractory visual hallucinations
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003962-41 Sponsor Protocol Number: 17/0909 Start Date*: 2020-03-23
    Sponsor Name:University College London
    Full Title: Trial of Ondansetron as a Parkinson’s HAllucinations Treatment
    Medical condition: Adults aged over 18 years with Parkinson's disease and visual hallucinations
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10047570 Visual hallucinations LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-001722-25 Sponsor Protocol Number: ZonMw80-83600-98-10226 Start Date*: 2013-08-27
    Sponsor Name:VU University Medical Center
    Full Title: Cholinesterase inhibitors to slow progression of visual hallucinations in Parkinson’s disease: a multi-center placebo-controlled trial (CHEVAL)
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003051-36 Sponsor Protocol Number: ACP-103-014 Start Date*: 2008-09-10
    Sponsor Name:Acadia Pharmaceuticals Inc
    Full Title: A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease
    Medical condition: Psychosis in Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037241 Psychosis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) ES (Completed) SE (Prematurely Ended) BE (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020008-31 Sponsor Protocol Number: ACP-103-019 Start Date*: 2013-10-25
    Sponsor Name:ACADIA Pharmaceuticals Inc
    Full Title: A Single center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer’s Disease
    Medical condition: Psychosis associated with Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002906-23 Sponsor Protocol Number: ACP-103-012 Start Date*: 2007-11-14
    Sponsor Name:Acadia Pharmaceuticals Inc
    Full Title: A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease
    Medical condition: Psychosis in Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037241 Psychosis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011799-31 Sponsor Protocol Number: DIM19 Start Date*: 2009-10-02
    Sponsor Name:Medivation, Inc
    Full Title: CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Six-Month Safety and Efficacy Study of Dimebon in Patients with Moderate-to-Severe Alzheimer’s Disease and Neuropsychiat...
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IE (Completed) ES (Completed) PT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004109-27 Sponsor Protocol Number: 2.12.05 Start Date*: 2006-03-24
    Sponsor Name:Neuropsychiatric clinic
    Full Title: A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies
    Medical condition: Parkinsons disease (PD)and dementia with Lewy bodies (DLB) are both common disease of the elderly. The majority of patients who survive for more than 10 years with PD eventually develope dementia ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000839-16 Sponsor Protocol Number: SM3-RS-2014 Start Date*: 2014-04-14
    Sponsor Name:HovedOrtoCentret, Rigshospitalet
    Full Title: The effect of intraoperative ketamine on opioid consumption and pain after spine surgery in opioid-dependent patients
    Medical condition: Postoperative pain
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10049124 Sedation during medical procedure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000376-41 Sponsor Protocol Number: VORIGENIPHARM Start Date*: 2019-06-18
    Sponsor Name:Fundación de Investigación del Hospital Universitario La Paz (FIBHULP)
    Full Title: Randomized and multicenter clinical trial to evaluate the effectiveness and efficiency of a voriconazole preemptive genotyping strategy in patients with risk of aspergillosis.
    Medical condition: Invasive fungal disease in the hematologic patient.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10017528 Fungal infectious disorders HLGT
    20.0 10021881 - Infections and infestations 10040054 Sepsis, bacteraemia, viraemia and fungaemia NEC HLT
    20.0 100000004851 10029355 Neutropenias HLT
    20.0 100000004851 10076734 Chemotherapy induced neutropenia LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061187 Haematopoietic neoplasm PT
    20.0 100000004865 10059041 Allogeneic peripheral haematopoietic stem cell transplant LLT
    20.0 100000004865 10059040 Autologous peripheral haematopoietic stem cell transplant LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005495-19 Sponsor Protocol Number: RVT-101-2001 Start Date*: 2016-06-13
    Sponsor Name:Axovant Sciences Inc.
    Full Title: A Phase 2b, double-blind, randomized, placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies (DLB).
    Medical condition: Dementia with Lewy Bodies
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024265-40 Sponsor Protocol Number: KETA-FAN Start Date*: 2011-10-27
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE
    Full Title: Perineural vs systemic N-methyl-D-aspartate (NMDA) receptors antagonism with ketamine as a reverser of peripheral and central sensitization in phantom limb pain
    Medical condition: Phantom limb pain
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10034804 Phantom limb pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001573-28 Sponsor Protocol Number: Uni-Koeln-320 Start Date*: 2007-11-26
    Sponsor Name:Universität zu Köln
    Full Title: Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial.
    Medical condition: Persons at risk of being prodromally symptomatic of psychosis (PAR)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003728-64 Sponsor Protocol Number: E2027-G000-201 Start Date*: 2018-12-03
    Sponsor Name:Eisai Ltd
    Full Title: A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies
    Medical condition: Dementia With Lewy Bodies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000202-20 Sponsor Protocol Number: RC-P0041 Start Date*: 2015-06-22
    Sponsor Name:Groupement des Hôpitaux de l’Institut Catholique de Lille (GHICL)
    Full Title: Effect and tolerance of ketamine's subcutaneous bolus during painful care, refractory of bedsore, ulcer, vascular wound care in palliative care units.
    Medical condition: Patients’ palliative care for bedsores, ulcers or vascular wounds, which are general characteristics of the patient population that will be included: usually elderly, undernourished and of multiple...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10047065 - Vascular disorders 10047079 Vascular injuries HLGT
    18.0 10018065 - General disorders and administration site conditions 10045285 Ulcer PT
    18.0 10040785 - Skin and subcutaneous tissue disorders 10036651 Pressure sore LLT
    18.0 10042613 - Surgical and medical procedures 10059513 Palliative care PT
    18.0 10040785 - Skin and subcutaneous tissue disorders 10040943 Skin ulcer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000192-86 Sponsor Protocol Number: NMSNabStudy Start Date*: 2017-09-15
    Sponsor Name:Medizinische Universität Innsbruck, Universitätsklinik für Neurologie
    Full Title: Nabilone for non-motor symptoms in Parkinson´s disease: A Randomized Placebo-controlled, double-blind, parallel-group, enriched enrollment randomized withdrawal Study
    Medical condition: Subjects with non-motor symptoms of Parkinson´s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003623-37 Sponsor Protocol Number: CAN-PDP Start Date*: 2020-02-12
    Sponsor Name:King's College London [...]
    1. King's College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: CANnabidiol for Parkinson’s Disease Psychosis
    Medical condition: Parkinson's disease psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10074835 Parkinson's disease psychosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004065-27 Sponsor Protocol Number: TTP488-303 Start Date*: 2018-03-19
    Sponsor Name:vTv THERAPEUTICS LLC
    Full Title: Open Label Extension Study For Continued Safety And Efficacy Evaluation Of Azeliragon In Patients With Mild Alzheimer's Disease
    Medical condition: MILD ALZHEIMER'S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    20.0 10029205 - Nervous system disorders 10012268 Dementia (excl Alzheimer's type) HLT
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10012294 Dementia of the Alzheimer's type, with delirium PT
    20.0 10029205 - Nervous system disorders 10012296 Dementia of the Alzheimer's type, with depressed mood PT
    20.0 10029205 - Nervous system disorders 10012293 Dementia of the Alzheimer's type, uncomplicated PT
    20.0 10029205 - Nervous system disorders 10012295 Dementia of the Alzheimer's type, with delusions PT
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    20.0 10029205 - Nervous system disorders 10012292 Dementia of the Alzheimer's type NOS LLT
    20.0 10029205 - Nervous system disorders 10066571 Progression of Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002005-19 Sponsor Protocol Number: TTP488-301 Start Date*: 2016-08-19
    Sponsor Name:vTv THERAPEUTICS LLC
    Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER REGISTRATION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TTP488 IN PATIENTS WITH MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE ...
    Medical condition: MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTINE
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    20.0 10029205 - Nervous system disorders 10012268 Dementia (excl Alzheimer's type) HLT
    20.0 10029205 - Nervous system disorders 10012296 Dementia of the Alzheimer's type, with depressed mood PT
    20.0 10029205 - Nervous system disorders 10012295 Dementia of the Alzheimer's type, with delusions PT
    20.0 10029205 - Nervous system disorders 10012294 Dementia of the Alzheimer's type, with delirium PT
    20.0 10029205 - Nervous system disorders 10012293 Dementia of the Alzheimer's type, uncomplicated PT
    20.0 10029205 - Nervous system disorders 10012292 Dementia of the Alzheimer's type NOS LLT
    20.0 10029205 - Nervous system disorders 10066571 Progression of Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 11:05:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA